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Liver transplantation in the management of 
bleeding oesophageal varices 
SHUNZABURO IW ATSUKI 
THOMAS E. STARZL 
The vast majority of patients who require liver transplants have significant 
portal venous hypertension, and their liver replacement is specifically aimed 
to treat three major complications of portal hypertension, namely, bleeding 
oesophageal varices, refractory ascites and encephalopathy (liver failure). 
Variceal haemorrhage and ascites can be treated effectively by various 
types of portal decompression surgery, but these procedures invariably 
decrease hepatic blood flow and hence worsen the function of an already 
compromised liver. The enthusiasm for treating oesophageal varices and 
ascites with non-selective portosystemic shunting started to wane more than 
two decades ago when it became apparent that the price of preventing 
haemorrhage from oesophageal varices and intractable ascites in this 
manner was dehumanizing encephalopathy and progressive hepatic dys-
function (Jackson et ai, 1971; Resnick et ai, 1974). 
With the development of potent and specific diuretic drugs, truly intract-
able ascites is extremely uncommon. When it does occur, more appropriate 
therapy than portosystemic shunt will often be a peritoneojugular shunt. 
Chronic hepatic encephalopathy can rarely be managed by medical means, 
and it is effectively treated only with liver transplantation. Thus, the 
principal problem in portal hypertension for which therapeutic planning 
must be done is the haemorrhage from oesophageal varices. 
Prophylactic and therapeutic uses of anti-(3-adrenergic agents and endo-
scopic sclerotherapy playa significant role in the management of oesophageal 
varices. Various types of portosystemic venous shunting have been evaluated 
as to their efficacy in preventing both haemorrhage from varices and 
accelerated decline of hepatic function. 
In our centre, where there is a chronic shortage of organs, Child's A 
patients who have had variceal bleeding are systemically screened for 
selective splenorenal shunts, performed electively. The procedure is being 
used on a trial basis because it is attended by a lower incidence of 
encephalopathy than is seen after non-selective shunts. Forty patients have 
been entered with no perioperative deaths but longer follow-up will be 
necessary to assess the validity of this approach. Five of the 40 have come to 
successful transplantation during the first 12 months after their Warren 
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shunts, which caused no technical difficulties at the time of grafting. In most 
cases. the shunt is removed by splenectomy. 
Liver transplantation has emerged as a safe and preferred treatment of 
many patients with end-stage liver diseases. the vast majority of which 
resulted in portal hypertension (Starzl et aI, 1982). Whether the graft is 
placed in the natural location (orthotopic) or ectopic site (heterotopic or 
auxiliary), liver transplantation invariably corrects the portal hypertension 
and treats most effectively bleeding varices, intractable ascites and 
encephalopathy. 
Except in isolated cases or small series, auxiliary transplantation has not 
provided satisfactory results. Consequently, we will concentrate in this 
chapter on the role of orthotopic liver transplantation in the management of 
portal hypertension. particularly of bleeding oesophageal varices. Also. we 
will examine the relationship of transplantation to other therapeutic 
modalities. 
INCIDENCE OF PORTAL HYPERTENSION, BLEEDING 
OESOPHAGEAL VARICES AND PORTAL VEIN THROMBOSIS 
AMONG LIVER TRANSPLANT RECIPIENTS 
The liver diseases of the first 1000 patients who received liver transplants 
under cyclosporin-steroid therapy (March 1980 to July 1987) are listed in 
Table 1 with the incidences of bleeding from oesophageal varices. 
More than 90% of the patients had end-stage chronic liver disease with 
significant portal hypertension. Furthermore, 22 patients had undergone 
non-selective shunt. 15 patients had undergone selective shunt, and five 
Table 1. Liver diseases of 1000 patients who received liver transplants between March 1980 and 
July 1987 and the incidences of bleeding from oesophageal varices. 
Diseases 
Cirrhosis 
(postnecrotic. cryptogenic. alcoholic) 
Biliary atresia 
Primarv biliary cirrhosis 
Liver-based inborn metabolic errors 
(a.-antitrypsin deficiency. Wilson's disease. etc.) 
Primary sclerosing cholangitis 
(with bile duct cancer) 
Hepatobiliary malignancy 
Fulminant hepatic failure 
Secondarv biliary cirrhosis 
Budd-Chiari svndrome 
Familial cholestatic syndrome 
Congenital hepatic fibrosis 
Others 
Total 
No. of 
patients 
319 
( 41) 
180 
166 
98 
82 
(8) 
45 
37 
21 
15 
15 
6 
16 
1000 
No. of 
oesophageal: 
bleeders • 
115 (36%) 
(15) (37%) 
38 (21 %) 
63 (38%) 
35 (36%) 
32 (39%) 
o 
o 
8 (38%) 
2 (13%) 
4 (27%) 
5 (83%) 
o 
302 (30<n:) 
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With these technical improvements. all types of portal hypertension 
(prehepatic. intrahepatic and posthepatic) or any combination of them can 
be effectively treated by orthotopic liver transplantation. This has widened 
the indications for treatment. 
RESULTS OF LIVER TRANSPLANTATION FOR PATIENTS 
WITH END-STAGE LIVER DISEASE AND BLEEDING FROM 
OESOPHAGEAL VARICES 
The overall survival rates of the first 1000 consecutive patients after liver 
transplantation with cyclosporin-steroid therapy (March 1980 to July 1987) 
were 74% at 1 year. 71 % at 2 years. 67% at 3 years. 65% at 4 years. and 64% 
at 5 years. when they were calculated by the method of Kaplan-Meier as of 
September 1987 (Iwatsuki et at. 1988a). The overall survival rates under 
cyclosporin-steroid therapy were unchanged when they were re-examined in 
the consecutive 1469 recipients as of July 1989 (Starzl and Demetris, 1990) 
and in the consecutive 1583 recipients as of July 1990 (Gordon et ai, 1991). 
However. the survival rates appeared to be improved starting in August 
1989 when a novel immunosuppressive drug, FK-506. was introduced to our 
clinical trial (Starzl et a1.1989; Todo et al. 1990. 1991; Fung et al. 1991). The 
i-year survival rate of 409 liver recipients treated with FK-506 has risen to 
85% as of Julv 1991. 
The survival rates of 302 variceal bleeders among the first 1000 consecutive 
liver recipients undercyclosporin-steroid therapy were 79% at 1 year, 74% at 
2 years. and 71 % aU. 4and5yearsasofFebruary 1988 (IwatsukietaI.1988b). 
There was no statistically significant difference in the survival rates among the 
patients with the five most common liver diseases shown in Table 1. 
The survival rates of the first consecutive 1000 liver recipients under 
cyclosporin-steroid therapy were updated as of September 1991, with a 
minimum follow-up of 4 years. One- to 5-year survival rates of the 1000 
patients were 73%. 69%, 67%. 65% and 64%, respectively. Those of the 
302 variceal bleeders were 80%, 77%, 75%. 74% and 71 %. respectively. 
Thus. the actuarial survival rates calculated in 1987 and 1988 precisely 
predicted the actual survival rates in 1991. 
LIVER TRANSPLANTATION FOR ALCOHOLIC CIRRHOSIS 
Alcoholic liver disease is the most common form of liver disease in the USA 
and other Western countries. However. the use of liver transplantation to 
treat patients with end-stage alcoholic cirrhosis has long been debated. We 
have been treating some of the patients with end-stage alcoholic liver disease 
by orthotopic liver transplantation. During the pre-cyclosporin era between 
1963 and 1979. 15 patients (18% of adult recipients) with alcoholic cirrhosis 
were transplanted. The first eight alcoholic recipients died peroperatively. 
However. four of the next seven patients survived more than 4 years. Three 
ofthe four patients are still alive and in good health after 17, 15 and 14 years. 
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respectively. None has returned to drinking. During the cyclosporin era 
between 1980 and 1989. 134 alcoholic patients (12% of adult recipients) 
received liver transplants. One- to 4-year survival rates were 81%, 75%. 
73% and 73%. respectively. as of July 1990 (Gordon et al. 1991). These 
survival rates were better than those of patients with viral hepatitis Band 
those with hepatic malignancy. Moreover. nearly 90% of the transplant 
survivors remained alcohol abstinent. 
Although abstinence was considered to be a favourable factor. a 'dry_' 
period of specific duration was not required before transplantation since this 
would invite svstematic falsification of the medical historv and because 
death would often be the price of a significant wait. Instead: acknowledge-
ment of the alcoholism problem is expected and commitments not to drink in 
the future are obtained from the patient and family. Going through a trauma 
of such magnitude as liver transplantation seemingly has been the starting 
point for long and permanent abstinence and usually for rehabilitation. For 
the last several years. however. extensive psychiatric and social support has 
been systematically provided. as the number of alcoholic liver transplant 
candidates has been increasing. The fact that relapses into alcoholism have 
been uncommon after liver transplantation weakens the potential objection 
that provision of a new liver is a futile gesture as well as a waste of an organ. 
ROLE OF LIVER TRANSPLANTATION IN THE MANAGEMENT 
OF BLEEDING OESOPHAGEAL VARICES 
The survival rates after liver transplantation for patients with advanced liver 
disease (Child's class C) who had had bleeding from oesophageal varices are 
quite satisfactory as presented earlier. and there is little doubt of the value of 
liver transplantation in this situation. Nevertheless, the results achieved by 
liver transplantation were compared with those reported in nine well-
studied control trials of therapeutic shunt operations (Table 2). All of these 
well-designed studies failed to show the survival superiority of non-selective 
shunt over medical management (Jackson et ai, 1971; Resnick et ai, 1974; 
Reynolds et ai, 1981), that of selective shunt over non-selective shunt (Conn 
et ai, 1981; Langer et ai, 1985; Millikan et ai, 1985), or that of selective shunt 
over chronic endoscopic sclerotherapy (Warren et ai, 1986; Rikkers et ai, 
1987; Teres et ai, 1987). 
As the outcomes of shunt operations. sclerotherapy or medical manage-
ment are highly influenced by the hepatic functional reserve of the patients, 
the results of one study cannot be simply compared with those of another. 
More than 75% of the patients in each report listed in Table 2 had good 
hepatic function or moderately impaired hepatic function (Child's class A 
and B), and fewer than 25% of them had advanced hepatic dysfunction 
(Child's class C). On the other hand. all the patients who received liver 
transplants had advanced or far-advanced hepatic dysfunction; many of 
them had been rejected for shunt operation and some of them had already 
had a shunt operation. Despite this severe disadvantage in preoperative 
condition, the survival rates of liver transplant recipients who had had 
, .,"-.... 
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variceal bleeding were better than or similar to those of patients who had 
other kinds of conventional therapy (Table 2). 
Because surgical therapy for oesophageal varices is usually withheld from 
the patients with advanced hepatic dysfunction (Child's class C), the 
literature contains few survival data for these patients. In Table 3 the results 
obtained by liver transplantation are compared with those achieved in 
patients with advanced hepatic dysfunction after conventional surgical 
therapy (Turcotte and Lambert. 1973; Yamamoto et al. 1976; Warren et al. 
1982; Rikkers et al. 1984; Chandler et ai, 1985; Spence and Johnston. 1985; 
Table 2. Survival comparison among various treatments for bleeding oesophageal varices 
(Child's classes A. B. and C). 
Survival rates (o/c) 
No. of 
Treatment patients I yr 2 yr 3 yr ~ yr 5 yr 
Jackson et al (1971) 
Non-selective shunt 67 80' 73' 62- 58- 55-
Medical 77 80 66 ~P- 35- 32-
Resnick et al (1974) 
Non-selective shunt 54 70- 58- 50- 48- 48-
Medical 25 67- 52' ~- 40' ~l· 
Reynolds et al ( 1981) 
Non-selective shunt 41 n' 64- 52' ~ 
Medical 37 60' ~K 36- 22 
Conn et al (1981) 
Selective shunt 24 76' 70' 
Non-selective shunt 29 70' 67' 
Langer et al ( 1985) 
Selective shunt 38 80- 76- 63" 54- 51' 
Non-selective shunt ~ 90- 85' 70' 56- 56' 
Millikan et al (1985) 
Selective shunt 26 85' 77' 65- 60' 55' 
Non-selective shunt 29 80- n' 70- 65- 60-
Warren et al (1986) 
Sc1erotherapyt 36 90' 84 82' 82' 
Selective shunt 35 70' 59 45' 45' 
Rikkers et al (1987) 
Sclerotherapy 30 77' 61 60' 50' 
Selective shunt:!: 27 75' 65 60' 39' 
Teres et al (1987) 
Selective shunt 57 90' 90' 82' 70' 70' 
Sclerotherapy 55 81' 75- 65- 65' 65' 
I watsuki et al (1 988b ) 
Liver transplantation 302 79 74 71 71 71 
Iwatsuki et al 
Liver transplantation 302 80 77 75 74 71 
(update 1991) 
* Value estimated from survival curve. 
t Sclerotherapy failures were rescued by surgical therapy. 
+ Twenty-three selective shunts and four non-selective shunts. 
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Iwatsuki et ai, 1988b). It is obvious that the survival rates of liver transplant 
recipients are far better than those achieved by conventional types of 
surgical therapy when the liver disease is advanced. 
Should all the cirrhotic patients be treated with liver transplantation when 
they have significant episodes of variceal haemorrhage? The answer is 
obviously no, because chronic endoscopic sclerotherapy is quite effective in 
controlling the haemorrhage from oesophageal varices, and the survival 
rates after sclerotherapy are superior or equal to those of shunt operations 
providing the sclerotherapy failures are rescued by surgical intervention 
(Warren et al. 1986; Rikkers et ai, 1987; Teres et ai, 1987). 
The role of endoscopic sclerotherapy in the treatment of bleeding 
oesophageal varices has been well established. However, the sclerotherapy 
cannot be effectively applied to gastric varices, and has its own special 
complications, such as oesophageal perforation or stricture of the distal 
oesophagus. The incidence of these complications rises astronomically when 
sclerotherapy is used during a crisis such as exists during active bleeding and 
especially if hepatic failure is a co-factor. 
Portosystemic shunt operations should be limited to those who have failed 
endoscopic sclerotherapy but who still have excellent hepatic function. 
Although the survival rates after transplantation are not jeopardized by 
previous porto systemic shunt operations, the actual liver transplant 
Table 3. Survival comparison among various treatments for bleeding oesophageal varices 
(Child's class C. poor liver function). 
Survival rates (%) 
No. of 
Treatment patients I yr 2 yr 3 yr 4 yr 5 yr 
Turcotte and Lambert (1973) 
Non-selective shunt 50 36 32 22 20 17 
Yamamoto et al (1976) 
Non-shunt operation 13 39 30 22 22 18 
Warren et al (1982) 
Selective shunt ? 60· 53· 45· 40· 35 
Non-selective shunt ? 50· 40· 37· 20· 15· 
Rikkers et al (1984) 
Shunt and non-shunt operationt 24 45 35· 30· 20· 17-
Chandler et al (1985) 
Shunt:!: 30 36 30 25 20 13 
Spence and Johnston (1985) 
Non-shunt operation 25 70 53 38 38 35 
Iwatsuki et al (1988b) 
Liver transplantation 302 79 74 71 71 71 
Iwatsuki et al 
Liver transplantation 302 80 77 75 74 71 
(update 1991) 
• Value estlmated from survival curve. 
t Fifteen non-selective shunts. seven selective shunts. and two non-shunt operations. 
:j: Both selective and non-selective operations. 
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procedures -for those patients are quite challenging even with recently 
developed sophisticated methods of portal vein reconstruction (Lerut et aI, 
1987: Tzakis et al. 1989: Mazzaferro et al. 1990; Stieber et aI, 1991). Among 
the various types of portosystemic shunt operations. the shunts created 
without hepatic hilum dissection (distal splenorenal shunt and mesocaval 
H-graft shunt) are more convenient for liver transplantation. However. the 
incidence of complete portal vein thrombosis after distal splenorenal shunt 
is approximately 10%. and that of partial thrombosis is approximately 15% 
(Henderson et al. 1982: Orozco et al. 1988: Spina et al. 1990: Jin and 
Rikkers. 1991). The thrombosis appears to develop early in the post-shunt 
period. 
Early reports of percutaneous transjugular portosystemic stent shunt (or 
transjugular intrahepatic portosystemic shunt. TIPS) are promising (Vinel et 
aI, 1985: Richteret al.1989; Zemelet aI, 1991). In this radiological procedure 
a balloon-expandable. self-expanding metallic stent is placed between the 
portal vein and the hepatic vein through the hepatic parenchyma. The 
technical success rate (75% or more) of TIPS and the patency rate (80% or 
more) of the stent at 1 year are incentives for further clinical trials. 
Although further experience and follow-up are needed to confirm the 
early results of this new technique. TIPS will further diminish the need for a 
surgical portosystemic shunt, and may revolutionize the treatment of bleed-
ing oesophageal varices. 
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